TCI Wealth Advisors’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-127
Closed -$3K 2493
2022
Q2
$3K Buy
+127
New +$3.76K ﹤0.01% 1858
2022
Q1
Sell
-103
Closed -$6K 2384
2021
Q4
$6K Buy
103
+35
+51% +$2.65K ﹤0.01% 1557
2021
Q3
$6K Hold
68
﹤0.01% 1487
2021
Q2
$4K Buy
+68
New +$3.46K ﹤0.01% 1612
2020
Q1
Sell
-99
Closed -$1K 1677
2019
Q4
$1K Buy
+99
New +$1.12K ﹤0.01% 1400

Other funds holding OPRX

TCI Wealth Advisors's OPRX Position: Q3 2022 in Review

TCI Wealth Advisors sold out of OptimizeRx (OPRX) in Q3 2022, closing a stake of 127 shares — an estimated $3K sold.

TCI Wealth Advisors first reported a position in OPRX in Q4 2019 and held it in 5 quarters. The position peaked at $6K in Q4 2021. 128 funds tracked by Wall St. Rank hold OPRX as of Q3 2022.

  • TCI Wealth Advisors reported no remaining OptimizeRx position as of Q3 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 127 OptimizeRx shares in Q3 2022, an estimated $3K.
  • TCI Wealth Advisors first reported a position in OptimizeRx in Q4 2019 and held it in 5 quarters.
  • TCI Wealth Advisors's OptimizeRx position peaked at $6K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2022.

Based on TCI Wealth Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.